Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MOGAT2 | Q3SYC2 | 3/20 | 0.53 |
| ▸ | MGAT2 | Q10469 | 3/20 | 0.52 |
| ▸ | SYK | P43405 | 9/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.51 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.51 |
| ▸ | FCER2 | P06734 | 3/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.49 |
| ▸ | MGAT1 | P26572 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5363913 | 0.93 | MDM2 (0.59) | MEN1ALOX15MAPK1KMT2AMOGAT2 | |
| SCHEMBL5361643 | 0.91 | MOGAT2 (0.52) | MEN1ALOX15MAPK1KMT2AMOGAT2 | |
| SCHEMBL5368257 | 0.90 | MEN1 (0.57) | MEN1ALOX15MAPK1KMT2AMOGAT2 | |
| SCHEMBL7137732 | 0.90 | MOGAT2 (0.55) | MEN1ALOX15MAPK1KMT2AMOGAT2 | |
| SCHEMBL5377343 | 0.89 | MOGAT2 (0.52) | MEN1ALOX15MAPK1KMT2AMOGAT2 | |
| SCHEMBL5363156 | 0.89 | MOGAT2 (0.55) | MEN1ALOX15MAPK1KMT2AMOGAT2 | |
| SCHEMBL5367311 | 0.88 | MEN1 (0.54) | MEN1ALOX15MAPK1KMT2AMOGAT2 | |
| SCHEMBL5369913 | 0.88 | MOGAT2 (0.56) | MEN1ALOX15MAPK1KMT2AMOGAT2 | |
| SCHEMBL5366974 | 0.86 | MOGAT2 (0.51) | MEN1ALOX15MAPK1KMT2AMOGAT2 | |
| SCHEMBL5368295 | 0.86 | SYK (0.68) | MAPK1MOGAT2MGAT2SYKNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | MEN1 3855/4885ALOX15 748/4885MAPK1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.